Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
Comprehensive Evaluation of Lipids, Lipoproteins, and Metabolites Associated with Gastrointestinal Cancer Risk.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sun Ming, Chen Weiwei, Cheng Xueni, Cui Hengyu, Huang Jianv, Huang Rong, Li Yumeng, Ma Yanan, Hang Dong
Аннотация
BACKGROUND: Emerging evidence indicates that lipid metabolism plays a crucial role in gastrointestinal (GI) cancers.
METHODS: This prospective cohort study included 112,655 cancer-free adults from the UK Biobank with metabolomics data at baseline. Multivariate Cox proportional hazards regression models were used to evaluate the associations between metabolites and GI cancers. LASSO regression was used to create metabolite risk scores, and their predictive performance for GI cancers was assessed using the C-statistic derived from the time-dependent ROC curves.
RESULTS: A total of 93, 95, 33, 97, 129, and 29 metabolites were associated with colorectal, pancreatic, esophageal, gastric, hepatocellular, and gallbladder/biliary tract cancers, respectively. Higher levels of phospholipids to total lipids in large high-density lipoprotein percentage and monounsaturated fatty acids to total fatty acids percentage were associated with increased risk of all GI cancers (HRs from 1.09 to 1.34). Conversely, higher levels of unsaturated fatty acids, polyunsaturated fatty acids, ratio of polyunsaturated to monounsaturated fatty acids, and docosahexaenoic acid were associated with lower risk of six GI cancers (HRs from 0.69 to 0.93). The highest tertile of metabolic risk scores were positively associated with all GI cancers (HRs from 1.86 to 6.42), and new prediction models showed moderate accuracy for five-year cancer incidence (C-statistics from 0.713 to 0.793).
CONCLUSIONS: Our findings highlight the significant role of lipid metabolism in GI cancers and provide potential noninvasive biomarkers for enhancing precise prevention.
IMPACT: Lipid metabolism holds clinical potential for precise prevention and early intervention of GI cancers.
METHODS: This prospective cohort study included 112,655 cancer-free adults from the UK Biobank with metabolomics data at baseline. Multivariate Cox proportional hazards regression models were used to evaluate the associations between metabolites and GI cancers. LASSO regression was used to create metabolite risk scores, and their predictive performance for GI cancers was assessed using the C-statistic derived from the time-dependent ROC curves.
RESULTS: A total of 93, 95, 33, 97, 129, and 29 metabolites were associated with colorectal, pancreatic, esophageal, gastric, hepatocellular, and gallbladder/biliary tract cancers, respectively. Higher levels of phospholipids to total lipids in large high-density lipoprotein percentage and monounsaturated fatty acids to total fatty acids percentage were associated with increased risk of all GI cancers (HRs from 1.09 to 1.34). Conversely, higher levels of unsaturated fatty acids, polyunsaturated fatty acids, ratio of polyunsaturated to monounsaturated fatty acids, and docosahexaenoic acid were associated with lower risk of six GI cancers (HRs from 0.69 to 0.93). The highest tertile of metabolic risk scores were positively associated with all GI cancers (HRs from 1.86 to 6.42), and new prediction models showed moderate accuracy for five-year cancer incidence (C-statistics from 0.713 to 0.793).
CONCLUSIONS: Our findings highlight the significant role of lipid metabolism in GI cancers and provide potential noninvasive biomarkers for enhancing precise prevention.
IMPACT: Lipid metabolism holds clinical potential for precise prevention and early intervention of GI cancers.